More recently, P2RY12 and CD49d were proposed to be robust markers for TAM-MGs and TAM-MDMs, respectively, after lineage-tracing studies were conducted in mice and validation studies were conducted with human glioma specimens [126, 129, 134]. This evidence concerns the gene P2RY12 and central nervous system cancer.